James Mohler, MD
James Mohler, MD
Associate Director and Senior Vice President, Translational Research
Chief, Inter-Institutional Academics
Professor of Oncology
Roswell Park Cancer Institute
Professor of Urology
Jacobs School of Medicine and Biomedical Sciences, University at Buffalo
Adjunct Professor of Urology
Member, Lineberger Comprehensive Cancer Center
University of North Carolina at Chapel Hill
Make an appointment online or call us at 1-800-Roswell Request an Appointment
Areas of Expertise:
Prostate cancer
Special Interests:
Role of androgen receptor in the growth of prostate cancer
Mechanism of prostate cancer growth after androgen deprivation therapy
Racial differences in the androgen axis
Active surveillance for low risk prostate cancer
Biography
James Mohler, MD, joined Roswell Park in 2003 and is Associate Director and Senior Vice President for Translational Research, Chair of the Department of Urology, and Professor of Oncology, at Roswell Park Cancer Institute, Professor of Urology at the University at Buffalo (UB) School of Medicine and Biomedical Sciences, and Adjunct Professor of Urology and Member of UNC-Lineberger Comprehensive Cancer Center at University of North Carolina.
Dr. Mohler earned his medical degree from the Medical College of Georgia and completed residency training in Surgery and Urology at the University of Kentucky Medical Center and a research fellowship in Urologic Oncology at The Johns Hopkins University School of Medicine.
Dr. Mohler is licensed by New York and North Carolina, a Diplomate of the National Board of Medical Examiners and the American Board of Urology, and a Fellow of the American College of Surgeons.
Dr. Mohler is Chair of the NCCN Prostate Cancer Guideline Committee, Past-President of the Society for Basic Urologic Research and Vice-Chair of the Urology Committee of the Alliance for Clinical Trials in Oncology (formerly CALGB) and is a member of the American Medical Association, American Association for the Advancement of Science, American Association for Cancer Research, American Urological Association and American College of Surgeons. He is a 2015 Distinguished Scholar Alumnus of the American Urological Association.
Dr. Mohler’s clinical practice focuses upon prostate cancer and robot-assisted laparoscopic surgery. His laboratory focuses upon the role of the androgen receptor in racial differences in prostate cancer aggressiveness and prostate cancer recurrence during androgen deprivation therapy. He has authored or co-authored more than 200 publications and book chapters, and a book “Androgen Action in Prostate Cancer.” He serves on the editorial board of The Prostate, Journal of the National Comprehensive Cancer Network, Journal of Robotic Surgery, and Therapeutic Advances in Urology, and reviews for several journals including Cancer, Cancer Research, Clinical Cancer Research, Journal of Molecular Endocrinology, Journal of Urology, Oncogene, Science Translational Medicine and Urology.
Background
Education and Training:
MD - Medical College of Georgia, Augusta, GA
Residency:
University of Kentucky, Lexington, KY
Duke University Medical Center, Durham, NC
Fellowship:
Johns Hopkins University School of Medicine, Baltimore, MD
Board Certification:
Diplomate, National Board of Medical Examiners
American Board of Urology
Fellow, American College of Surgeons
- Abdel-Wahab M, Mahmoud O, Merrick G, Hsu I-CJ, Arterbery VE, Ciezki JP, Frank SJ, Mohler JL, Moran BJ, Rosenthal SA, Rossi Jr CJ, Yamada Y. ACR Appropriateness Criteria® external-beam radiation therapy treatment planning for clinically localized prostate cancer. Journal of the American College of Radiology : JACR 2012; 94:233-238
- Ciezki JP, Hsu I-CJ, Abdel-Wahab M, Arterbery VE, Frank SJ, Mohler JL, Moran BJ, Rosenthal SA, Rossi CJ, Yamada Y, Merrick G. American College of Radiology Appropriateness Criteria((R))--locally advanced (high-risk) prostate cancer. Clinical oncology 2012; 241:43-51
- Arab L, Su LJ, Steck SE, Ang A, Fontham ETH, Bensen JT, Mohler JL. Coffee consumption and prostate cancer aggressiveness among African and Caucasian Americans in a population-based study. Nutrition and cancer 2012; 645:637-642
- Titus MA, Zeithaml B, Kantor B, Li X, Haack K, Moore DT, Wilson EM, Mohler JL, Kafri T. Dominant-negative androgen receptor inhibition of intracrine androgen-dependent growth of castration-recurrent prostate cancer. PloS one 2012; 71:e30192
- Sucheston LE, Bensen JT, Xu Z, Singh PK, Preus L, Mohler JL, Su LJ, Fontham ET, Ruiz B, Smith GJ, Taylor JA. Genetic ancestry, self-reported race and ethnicity in african americans and european americans in the PCaP cohort. PloS one 2012; 73:e30950
- Song L, Mishel M, Bensen JT, Chen RC, Knafl GJ, Blackard B, Farnan L, Fontham E, Su LJ, Brennan CS,Mohler JL, Godley PA. How does health literacy affect quality of life among men with newly diagnosed clinically localized prostate cancer? Findings from the North Carolina-Louisiana Prostate Cancer Project (PCaP). Cancer 2012; 11815:3842-3851
- Moore AD, Hamilton JB, Knafl GJ, Godley PA, Carpenter WR, Bensen JT, Mohler JL, Mishel M. Patient Satisfaction Influenced by interpersonal treatment and communication for African American men: the North Carolina-Louisiana Prostate Cancer Project (PCaP). American journal of men's health 2012;65:409-419
- Schmidt LJ, Duncan K, Yadav N, Regan KM, Verone AR, Lohse CM, Pop EA, Attwood K, Wilding G, Mohler JL, Sebo TJ, Tindall DJ, Heemers HV. RhoA as a mediator of clinically relevant androgen action in prostate cancer cells. Molecular endocrinology (Baltimore, Md.) 2012; 265:716-735
- Azzouni F, Mohler J. Role of 5alpha-reductase inhibitors in benign prostatic diseases. Prostate cancer and prostatic diseases 2012; 153:222-230
- Azzouni F, Mohler J. Role of 5alpha-reductase inhibitors in prostate cancer prevention and treatment.Urology 2012; 796:1197-1205
- Azzouni F, Godoy A, Li Y, Mohler J. The 5 alpha-reductase isozyme family: a review of basic biology and their role in human diseases. Advances in urology 2012; 2012 :530121
- Godoy A, Kawinski E, Li Y, Oka D, Alexiev B, Azzouni F, Titus MA, Mohler JL. 5alpha-reductase type 3 expression in human benign and malignant tissues: a comparative analysis during prostate cancer progression. Prostate 2011; 7110:1033-1046
- Moran BJ, Derose P, Hsu I-CJ, Abdel-Wahab M, Arterbery VE, Ciezki JP, Frank SJ, Mohler JL, Rosenthal SA, Rossi Jr CJ, Yamada Y, Merrick GS. ACR Appropriateness Criteria® definitive external beam irradiation in stage T1 and T2 prostate cancer. American journal of clinical oncology 2011; 346:636-647
- Mohler JL, Titus MA, Bai S, Kennerley BJ, Lih FB, Tomer KB, Wilson EM. Activation of the androgen receptor by intratumoral bioconversion of androstanediol to dihydrotestosterone in prostate cancer.Cancer research 2011; 714:1486-1496
- Expert Panel on Radiation Oncology-Prostate, Yamada Y, Rossi CJ, Rosenthal SA, Moran BJ, Mohler JL, Hahn NM, Ciezki JP, Abdel-Wahab M, Hsu IC, Arterbery VE, Frank SJ, Merrick G. American College of Radiology Appropriateness Criteria permanent source brachytherapy for prostate cancer.Brachytherapy 2011; 105:357-362
- Godoy A, Montecinos VP, Gray DR, Sotomayor P, Yau JM, Vethanayagam RR, Singh S, Mohler JL, Smith GJ. Androgen deprivation induces rapid involution and recovery of human prostate vasculature.American journal of physiology. Endocrinology and metabolism 2011; 3002:E263-E275
- Chadha KC, Nair BB, Chakravarthi S, Zhou R, Godoy A, Mohler JL, Aalinkeel R, Schwartz SA, Smith GJ.Enzymatic activity of free-prostate-specific antigen (f-PSA) is not required for some of its physiological activities. Prostate 2011; 7115:1680-1690
- Xu Z, Bensen JT, Smith GJ, Mohler JL, Taylor JA. GWAS SNP Replication among African American and European American men in the North Carolina-Louisiana prostate cancer project (PCaP). Prostate2011; 718:881-891
- Su LJ, Arab L, Steck SE, Fontham ET, Schroeder JC, Bensen JT, Mohler JL. Obesity and prostate cancer aggressiveness among African and Caucasian Americans in a population-based study. Cancer epidemiology, biomarkers and prevention 2011; 205:844-853
- Mohler JL, Titus MA, Wilson EM. Potential prostate cancer drug target: bioactivation of androstanediol by conversion to dihydrotestosterone. Clinical cancer research 2011; 1718:5844-5849
- Hayn MH, Orom H, Shavers VL, Sanda MG, Glasgow M, Mohler JL, Underwood III W. Racial/ethnic differences in receipt of pelvic lymph node dissection among men with localized/regional prostate cancer. Cancer 2011; 11720:4651-4658
- Kim HL, Puymon MR, Qin M, Guru K, Mohler JL. A method for using life tables to estimate lifetime risk for prostate cancer death. Journal of the National Comprehensive Cancer Network : JNCCN 2010;82:148-154
- Wu Y , Chhipa RR , Cheng J , Zhang H , Mohler JL , Ip C. Androgen receptor-mTOR crosstalk is regulated by testosterone availability: implication for prostate cancer cell survival. Anticancer research 2010;3010:3895-3901
- Lih FB, Titus MA, Mohler JL, Tomer KB. Atmospheric pressure photoionization tandem mass spectrometry of androgens in prostate cancer. Analytical chemistry 2010; 8214:6000-6007
- Singh SS, Ray MJ, Davis W, Marshall JR, Sakr WA, Mohler JL. Manual and automated systems in the analysis of images from prostate tissue microarray cores. Analytical and quantitative cytology and histology 2010; 326:311-319
- Mohler J, MacVicar G, Plimack ER, Pow-Sang JM, Roach III M, Rohren E, Roth BJ, Shrieve DC, Smith MR, Srinivas S, Twardowski P, Lange PH, Kuettel M, Kawachi M, Bahnson RR, Boston B, Busby JE, D'Amico A, Eastham JA, Enke CA, George D, Horwitz EM, Huben RP, Kantoff P, Walsh PC. NCCN clinical practice guidelines in oncology: prostate cancer. Journal of the National Comprehensive Cancer Network : JNCCN 2010; 82:162-200
- Chhipa RR, Wu Y, Mohler JL, Ip C. Survival advantage of AMPK activation to androgen-independent prostate cancer cells during energy stress. Cellular signalling 2010; 2210:1554-1561
- Cheng J, Wu Y, Mohler JL, Ip C. The transcriptomics of de novo androgen biosynthesis in prostate cancer cells following androgen reduction. Cancer biology and therapy 2010; 912:1033-1042
- Ray MJ, Singh SS, Davis W, McCann WE, Mohler JL, Marshall JR. Variability in visual segmentation of digitized prostate tissue microarray cores. Analytical and quantitative cytology and histology 2010;326:301-310
- Titus MA, Tan J-A, Gregory CW, Ford OH, Subramanian RR, Fu H, Wilson EM, Mohler JL, French FS. 14-3-3{eta} Amplifies Androgen Receptor Actions in Prostate Cancer. Clinical cancer research 2009;1524:7571-7581
- Guru KA, Perlmutter AE, Sheldon MJ, Butt ZM, Zhang S, Tan W, Wilding G, Kim HL, Mohler JL. Apical margins after robot-assisted radical prostatectomy: does technique matter?. Journal of endourology2009; 231:123-127
- Morrison C, Cheney R, Johnson CS, Smith G, Mohler JL. Central quadrant procurement of radical prostatectomy specimens. Prostate 2009; 697:770-773
- Singh SS, Wilding GE, Chandrasekhar R, Ivanova A, Maygarden SJ, Pop EA, Jeyaraj DA, Ford III OH, Mehedint DC, Mohler JL. Comparison of ACINUS, caspase-3, and TUNEL as apoptotic markers in determination of tumor growth rates of clinically localized prostate cancer using image analysis.Prostate 2009; 6915:1603-1610
- Guru KA, Menon M, Mohler JL, Wilding G, Underwood W, Glasgow M, Bienko M, Piacente P, Chandrasekhar R, Hussain A, Peabody JO. Current status of robot-assisted surgery in urology: a multi-national survey of 297 urologic surgeons. Canadian journal of urology 2009; 164:4736-4741
- Parsons JK, Newman VA, Mohler JL, Pierce JP, Flatt S, Messer K, Marshall J. Dietary intervention after definitive therapy for localized prostate cancer: results from a pilot study. Canadian journal of urology2009; 163:4648-4654
- Butt ZM, Fazili A, Tan W, Wilding GE, Filadora V, Kim HL, Mohler JL, O'Leary KA, Guru KA. Does the presence of significant risk factors affect perioperative outcomes after robot-assisted radical cystectomy?. BJU international 2009; 1047:986-990
- Yuh BE, Ciccone J, Chandrasekhar R, Butt ZM, Wilding GE, Kim HL, Mohler JL, Guru KA. Impact of previous abdominal surgery on robot-assisted radical cystectomy. JSLS : Journal of the Society of Laparoendoscopic Surgeons 2009; 133:398-405
- Karpf A, Bai S, James SR, Mohler JL, Wilson EM. Increased expression of androgen receptor coregulator MAGE-11 in prostate cancer by DNA hypomethylation and cyclic AMP. Molecular cancer research : MCR2009; 74:523-535
- Grubb RL, Petricoin EF, Liotta LA, Linehan WM, Rubin M, Chinnaiyan A, Mohler JL, Pinto PA, Deng JH, Wulfkuhle JD. Pathway biomarker profiling of localized and metastatic human prostate cancer reveal metastatic and prognostic signatures. Journal of proteome research 2009; 86:3044-3054
- Shah SK, Trump DL, Sartor O, Tan W, Wilding GE, Mohler JL. Phase II study of Dutasteride for recurrent prostate cancer during androgen deprivation therapy. Journal of urology 2009; 1812:621-626
- Carpenter WR, Fontham ETH, Su LJ, Rayford W, Bensen J, Mishel M, Finnegan T, Talcott JA, Clark JA, Godley PA, Mohler JL. Racial differences in trust and regular source of patient care and the implications for prostate cancer screening use. Cancer 2009; 11521:5048-5059
- Glinianski M, Guru KA, Zimmerman G, Mohler J, Kim HL. Robot-assisted ureterectomy and ureteral reconstruction for urothelial carcinoma. Journal of endourology 2009; 231:97-100
- Yuh B, Butt Z, Fazili A, Piacente P, Tan W, Wilding G, Mohler J, Guru K. Short-term quality-of-life assessed after robot-assisted radical cystectomy: a prospective analysis. BJU international 2009; 1036:800-804
- Guru KA, Perlmutter AE, Butt ZM, Piacente P, Wilding GE, Tan W, Kim HL, Mohler JL. The learning curve for robot-assisted radical cystectomy. JSLS : Journal of the Society of Laparoendoscopic Surgeons 2009;134:509-514
- Mohler JL. A role for the androgen-receptor in clinically localized and advanced prostate cancer. Best practice and research. Clinical endocrinology and metabolism 2008; 222:357-372
- Wang H, Sun D, Ji P, Mohler J, Zhu L. An AR-Skp2 pathway for proliferation of androgen-dependent prostate-cancer cells. Journal of cell science 2008; 121Pt 15:2578-2587
- Parsons JK, Newman VA, Mohler JL, Pierce JP, Flatt S, Marshall J. Dietary modification in patients with prostate cancer on active surveillance: a randomized, multicentre feasibility study. BJU international2008; 10110:1227-1231
- Ford BS, Sharma S, Rezaishiraz H, Huben RS, Mohler JL. Effect of perioperative blood transfusion on prostate cancer recurrence. Urologic oncology 2008; 264:364-367
- Butt ZM, Perlmutter AE, Piacente PM, Wilding G, Tan W, Kim HL, Mohler JL, Guru KA. Impact of body mass index on robot-assisted radical cystectomy. JSLS : Journal of the Society of Laparoendoscopic Surgeons 2008; 123:241-245
- Yuh B, Padalino J, Butt ZM, Tan W, Wilding GE, Kim HL, Mohler JL, Guru KA. Impact of tumour volume on surgical and pathological outcomes after robot-assisted radical cystectomy. BJU international 2008;1027:840-843
- Jenkins LC, Nogueira M, Wilding GE, Tan W, Kim HL, Mohler JL, Guru KA. Median lobe in robot-assisted radical prostatectomy: evaluation and management. Urology 2008; 715:810-813
- Camoriano M, Kinney SR, Moser MT, Foster BA, Mohler JL, Trump DL, Karpf AR, Smiraglia DJ. Phenotype-specific CpG island methylation events in a murine model of prostate cancer. Cancer research 2008;6811:4173-4182
- Guru KA, Sternberg K, Wilding GE, Tan W, Butt ZM, Mohler JL, Kim HL. The lymph node yield during robot-assisted radical cystectomy. BJU international 2008; 1022:231-234; discussion 234
- Parsons JK, Newman V, Mohler JL, Pierce JP, Paskett E, Marshall J, Cancer and Leukemia Group B. The Men's Eating and Living (MEAL) study: a Cancer and Leukemia Group B pilot trial of dietary intervention for the treatment of prostate cancer. Urology 2008; 723:633-637
- Singh SS, Li Y, Ford OH, Wrzosek CS, Mehedint DC, Titus MA, Mohler JL. Thioredoxin Reductase 1 Expression and Castration-recurrent Growth of Prostate Cancer. Translational oncology 2008; 13:153-157
- Mahajan NP, Liu Y, Majumder S, Warren MR, Parker CE, Mohler JL, Earp HS, Whang YE. Activated Cdc42-associated kinase Ack1 promotes prostate cancer progression via androgen receptor tyrosine phosphorylation. Proceedings of the National Academy of Sciences of the United States of America2007; 10420:8438-8443
- Singh SS, Mehedint DC, Ford OH 3rd, Maygarden SJ, Ruiz B, Mohler JL. Feasibility of constructing tissue microarrays from diagnostic prostate biopsies. Prostate 2007; 6710:1011-1018
- Guru KA, Kuvshinoff BW, Pavlov-Shapiro S, Bienko MB, Aftab MN, Brady WE, Mohler JL. Impact of robotics and laparoscopy on surgical skills: A comparative study. Journal of the American College of Surgeons 2007; 2041:96-101
- Guru KA, Seereiter PJ, Sfakianos JP, Hutson AD, Mohler JL. Is a cystogram necessary after robot-assisted radical prostatectomy? . Urologic oncology 2007; 256:465-467
- Park SY, Yu X, Ip C, Mohler JL, Bogner PN, Park YM. Peroxiredoxin 1 interacts with androgen receptor and enhances its transactivation. Cancer research 2007; 6719:9294-9303
- Guru KA, Nogueira M, Piacente P, Nyquist J, Mohler JL, Kim HL. Rapid communication: robot-assisted anterior exenteration: technique and initial series. Journal of endourology 2007; 216:633-639
- Guru KA, Kim HL, Piacente PM, Mohler JL. Robot-assisted radical cystectomy and pelvic lymph node dissection: initial experience at Roswell Park Cancer Institute. Urology 2007; 693:469-474
- Guru KA, Wilding GE, Piacente P, Thompson J, Deng W, Kim HL, Mohler J, O'Leary K. Robot-assisted radical cystectomy versus open radical cystectomy: assessment of postoperative pain. Canadian journal of urology 2007; 146:3753-3756
- Sharma S, Kim HL, Mohler JL. Routine pelvic drainage not required after open or robotic radical prostatectomy. Urology 2007; 692:330-333